MetaCap

Serina Therapeutics Inc. (SER)

NYSE: SERHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.12-0.08 (-6.67%)

At close: Nov 20, 3:59 PM ET · Delayed 15 min

SER stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.76M
EPS (TTM)
-$1.63
52-week range
1.06 – 4.26
Day range
1.06 – 1.26
Volume / Avg
62.15K / 68.98K
Beta
—
Next earnings
Nov 26, 2026

52-week range

$1.06$4.26

SER stock today

On Nov 20, SER ended the session at $1.12, shedding $0.08 (6.67%), versus the S&P 500's 3.70% decline. At this level, SER sits near the bottom of its 52-week range of $1.06 to $4.26: 73.7% below the high, set on Nov 28, 2025 and 5.7% above the low. SER is down 41.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 71.9%.

Serina Therapeutics has posted a net loss over the last twelve months (EPS of -$1.63), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 26.

Summary generated from market data by MetaCap's automated system. Methodology

About Serina Therapeutics

Company profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Steven A. Ledger
Headquarters
Huntsville, AL
Employees
16
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Serina Therapeutics generated $130,000 in revenue, up 132.1% from fiscal 2024. Serina Therapeutics reported a net loss of $19.2 million, compared with a loss of $11.1 million a year earlier. Operating margin was -18478.5%.

Serina Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$130.00K$56.00K$3.15M$34.00K$144.00K
Growth+132.14%-98.22%+9173.53%-76.39%-60.11%
Net income$-19.18M$-11.14M$5.27M$-10.46M$-8.68M
EPS (diluted)$-1.91$-1.51$0.73$-9.70$-0.23

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$9.50+748.21%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 26, 2026
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.45 vs —

SER news

All SER news

Serina Therapeutics peers

Health Care sector
SER peer companies
CompanyPrice% ChgMarket capCompare
NXTCNextCure Inc.6.45-4.87%$29.53Mvs SER
NNVCNanoViricides Inc.1.14-2.56%$29.13Mvs SER
RNTXRein Therapeutics Inc.0.3369-8.38%$29.06Mvs SER
ATHEAlterity Therapeutics Limited ADR1.52-8.16%$29.02Mvs SER
AYTUAytu BioPharma Inc.2.660.00%$28.91Mvs SER
PMNProMIS Neurosciences Inc.3.16-1.56%$28.43Mvs SER
FLNAFilana Therapeutics Inc.0.6413+14.52%$32.26Mvs SER
GRDXGridAI Technologies Corp.3.16-8.41%$32.44Mvs SER

Indexes, lists and sector

Serina Therapeutics stock FAQ

What is Serina Therapeutics's stock price today?

SER last traded at $1.12 as of Nov 20, 3:59 PM EST, down 6.67% on the day. Prices are delayed at least 15 minutes.

Does Serina Therapeutics pay a dividend?

No. Serina Therapeutics does not currently pay a regular cash dividend.

When is Serina Therapeutics's next earnings date?

Serina Therapeutics is expected to report earnings on Thursday, November 26, 2026.

Who is Serina Therapeutics's CEO?

Mr. Steven A. Ledger is the chief executive officer of Serina Therapeutics Inc., which has about 16 employees.

Has SER ever split its stock?

Yes. The most recent SER stock split was a 28-for-1000 split on Mar 15, 2024.

What is the SER 52-week high?

The 52-week high for SER is $4.26 and the 52-week low is $1.06. The stock is currently 73.7% below its high.

Compare SER